Organization
Institut de Cancérologie de l’Ouest
4 abstracts
Abstract
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,
Abstract
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).Org: Gustave Roussy Département d'Organisation du Parcours Patient, Institut Paoli Calmettes, Centre Hospitalier Lyon Sud, ICM Val d'Aurelle, CHU Nantes-Department of Hepato-Gastroenterology,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed and resected glioblastoma: PAZOGLIO trial.Org: Centre Antoine-Lacassagne, University Côte d'Azur, ICO Cancer Center, Institut de Cancérologie de l’Ouest, CHU de Nice,